Subintimal angioplasty for femoro-popliteal occlusive disease  by Markose, George et al.
EVIDENCE SUMMARY
Jan D. Blankensteijn, MD, PhD, Section Editor
Subintimal angioplasty for femoro-popliteal
occlusive disease
George Markose, MBBS, MRCP, FRCR,a Fiona N. A. C. Miller, MBBS, MRCP, FRCR,b and
Amman Bolia, MBChB, FRCR,c London, Suffolk, and Leicester, United Kingdom
There has been a longstanding debate about the roles of surgical bypass graft, percutaneous transluminal angioplasty,
subintimal angioplasty, and conservative management for femoro-popliteal occlusive disease. Subintimal angioplasty was
first described in 1987 as a method of performing an endovascular arterial bypass. The subintimal space at the start of the
occlusion is entered with a catheter and a wire loop is used to cross the occlusion and reenter the vessel lumen distally. In
patients with critical limb ischemia, there is high quality evidence demonstrating that the limb salvage rate and
amputation-free survival rates for surgery and endovascular treatment are similar, but surgery is more expensive than
angioplasty in the short term. In patients with intermittent claudication, surgical bypass using an autologous saphenous
vein graft is currently believed to be the gold standard, but this is increasingly questioned in the light of recent advances
in endovascular techniques. Surgical bypass with vein graft offers a 2-year patency of 81%, compared with 67% for a
polytetrafluoroethylene (PTFE) graft and at best 67% for subintimal angioplasty. The better patency offered by surgery
must be balanced against a higher morbidity and mortality. To conclude, subintimal angioplasty is an extremely valuable
technique in the management of critical limb ischemia. Based on the evidence to date, this technique is likely to have an
increasing role in the management of intermittent claudication over the coming years, particularly if the risk of general
anaesthesia is high or there is no suitable vein. (J Vasc Surg 2010;52:1410-6.)Subintimal angioplasty (SIA) was first described in 1987
to treat femoro-popliteal occlusive disease in intermittent
claudication.1,2 The technique uses a catheter to enter the
subintimal space at or above the level of occlusion. A guide-
wire is passed through the catheter and a wire loop created.
The loop is used to cross the occlusion subintimally and
reenter the vessel lumen beyond the occlusion. SIA has in-
creased in popularity over recent years, particularly in critical
limb ischemia (CLI), but remains controversial in patients
with intermittent claudication (IC) because of a perceived
high complication rate and low long-term patency.
Treatment options for femoro-popliteal occlusive disease
fall into several broad categories: medical management with
graded exercise, surgical femoro-popliteal bypass (BG), per-
cutaneous transluminal angioplasty (PTA), and subintimal
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1410angioplasty (SIA). The choice of management will vary
with patient and clinician preference, local expertise and the
TransAtlantic InterSociety Consensus II3 stratification of
the vascular lesion. The risk-benefit analysis for SIA will
depend on the clinical presentation and will also be affected
by the presence of comorbidities such as cardiovascular or
pulmonary disease.
This report aims to review the evidence published to
date in peer-reviewed journals relating to subintimal angio-
plasty and to address the following questions:
(1) What are the outcomes and complications of SIA when
compared to other treatments?
(2) What factors maximize the efficacy of SIA and reduce
the associated risks?
Particular attention will be paid to technical success, long-
term patency, secondary patency with surveillance and
complication rates as well as limb salvage rates in CLI. SIA
will be compared with the alternative treatments using the
limited data available, and further research areas will be
identified.
METHODS
Studies were identified by searches of the MEDLINE
and Cochrane databases. All Cochrane reviews under the
subject heading “peripheral vascular diseases” were in-
cluded. Publications already known to the authors were
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identify reviews and meta-analyses using the keywords
“femoro-popliteal bypass”, “critical ischemia” and “an-
gioplasty”, and “claudication” and “angioplasty”. A fur-
ther search was performed to identify all publications
using the term “subintimal angioplasty”. Over 150 pub-
lications were excluded after reading the title or abstract,
and 89 publications were selected to be read in full.
Studies included in subsequent systematic reviews and
meta-analyses were not re-reviewed in full. Levels of
evidence were assigned to all studies based on the meth-
ods described using the Oxford scheme,4 which covers
prevalence as well as comparative studies. Follow-up of
consecutive patients after intervention was regarded as a
clinical cohort rather than a case series.
RESULTS
The outcomes of SIA
Technical success and patency (Table I).5-12 Tech-
nical success rates (good flow through the lesion immedi-
ately after intervention) are typically between 80% and 90%.
The time at which primary patency is measured and the
method of measurement (clinically, ankle-brachial pressure
index [ABPI], ultrasound, angiography) both vary widely
between studies. Outcomes for patients presenting with
CLI are known to be worse than for patients with IC, but
many studies do not differentiate between these types of
patient when reporting a value for patency – this will tend to
reduce the estimates of patency in IC. Patency rates quoted
at 1 year vary between 56% and 70%. This compares to a
reported primary patency of BG of 81% at 2 years.13 Some
studies also report secondary patency, patency with surveil-
lance and early reintervention, which is typically higher for
both SIA and BG.10
Limb salvage. The reported limb salvage rates for SIA
(Table I) are as high as 89% at 1 year.5 Sultan el al9 report a
limb salvage rate of 73% at 5 years for SIA compared with
71% for BG. The Bypass versus Angioplasty in Severe
Ischaemia of the Leg (BASIL) trial7 reports no difference in
amputation-free survival between angioplasty-first or surgery-
first management protocols at 6 months, though it does
not differentiate between PTA and SIA.
Clinical benefit of subintimal angioplasty vs other
treatment strategies
In the majority of studies, patency following intervention
in patients with IC has been taken as a surrogate for an
improvement in walking ability, which itself is not commonly
reported in studies of SIA or BG. This causes difficulty when
directly comparing SIA with graded exercise therapy that has
been shown in a Cochrane review by Watson et al14 to
produce a 50% to 200% increase in walking ability although
with no effect on ABPI (Table II).7,9,11,13,14
Some would argue that the more familiar technique of
intraluminal angioplasty is safer and more durable. How-
ever, Antusevas et al11 describe an increased technical suc-
cess rate for SIA compared to PTA of 88% vs 81% and ahigher primary patency at 2 years for SIA compared with
PTA of 69% vs 43%. Further, Axisa et al15 found no
difference in the complication rate between the two tech-
niques.
Factors affecting technical success, long-term patency
and complications
To knowwhen SIA is the best treatment, it is important
to know what factors affect the technical success rate,
patency and clinical outcome, as well as which factors are
associated with a higher complication rate.
Technical success. The success rate of SIA and BG is
lower in patients presenting with CLI than in patients
presenting with IC.15 Technical success rates for SIA im-
prove with increasing experience of the procedure.16
The nature of the lesion affects both the success rate and the
long-term patency: more distal and longer lesions are more
technically challenging and less likely to stay open, and the
presence of calcification is associated with a lower success
rate.
The major causes of technical failure in SIA are failure
of reentry and elastic recoil (Table III). 6,8-12,13,15,17,18
Reentry. The use of the Outback reentry catheter
(Cordis, Bridgewater, NJ) and the use of a retrograde
popliteal artery approach have both been shown to improve
technical success rates following failed initial reentry. In-
deed, Noory et al19 report a 98.2% technical success rate in
patients with previous downstream attempts and reentry
failure.
Patency. Patency is adversely affected by renal insuffi-
ciency, current smoking and diabetes and the number of
patent runoff vessels.6 Many believe that recanalization of
the distal vessels also improves patency, but as yet the
evidence is inconclusive. It is known that flow on angiog-
raphy rather than the appearance of the “still image” is the
best guide to success. Evidence supporting this comes from
the finding that the value of the ABPI after SIA is an
independent predictor of avoiding CLI or IC after success-
ful revascularization.6 Further support comes from Ascher
et al20 demonstrating that patency is related to the flow in
the popliteal artery measured with ultrasound immediately
after angioplasty. Furthermore, surveillance of the subinti-
mal tract with early reintervention has been shown to
improve long-term patency.21
Stenting. The case for primary stenting in the superfi-
cial femoral artery (SFA) remains unproven. The problems
of neo-intimal hyperplasia in the SFA as well as stent
fracture remain a concern. A Cochrane review of angio-
plasty alone vs angioplasty and primary stenting undertaken
by Twine et al17 concluded that although there is limited
benefit to stenting in the SFA, this cannot be recom-
mended routinely. It is also not clear that stents placed in
the subintimal space will behave in the same way as those
placed within the vessel lumen. Adjuvant stenting for elas-
tic recoil or a lesion that cannot be dilated adequately is
commonly performed, although no publication could be
identified that quantified the effect of this practice on
outcomes.
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Study first
author Study design No. of studies/patients
Technical success
rate Primary patency
Limb salvage
rate
Level of evidence
for symptom
prevalence study
Bown5 Meta-analysis of all
follow-up
studies of
infrainguinal
SIA cohorts
published
between
between 1989
and 2008.
37 studies (prospective
and reterospective),
2810 limbs overall.
Separate analysis
performed for each
individual outcome
85.7% (36
studies, 2810
limbs)
55.8% at 12 months
(19 studies, 1342
limbs)
89.3% at 12
months (18
studies, 1322
limbs)
1a-/2a
Met6 Systematic review
of SIA outcomes
in peripheral
arterial occlusive
disease.
23 studies (prospective
and reterospective),
1549 patients
80%-90% Around 50%. Clinical
success rate 50-
70% at 1 year.
80%-90%. 1a-/2a
BASIL7 Randomized
controlled trial
of angioplasty
first vs. surgery
first in CLI
452 patients from 27
hospitals presenting
with CLI and
infrainguinal disease
to surgery first or
angioplasty first
Not reported Not reported Angioplasty first
(approximately
50%
subintimal)
90% at 6
months.
1b
Setacci8 Prospective follow-
up of SIA with
adjuvant use of
the Outback
reentry device
and stenting in
consecutive
patients
presenting to a
single centre
with CLI
145 procedures 90% (140/145)
compared
with 83.6%
(121/145)
without re-
entry device.
70%, 53% and 34% at
1, 2, and 3 years
88%, 76%, and
49% at 1, 2,
and 3 years
1b
Sultan9 Prospective non-
randomized
controlled study
of SIA vs. BG in
patients with CLI
SIA 190, BG 119 99.5% for SIA
vs 100% for
BG
72.8% at 5 years 72.9% at 5 years 1b
Desgranges10 Prospective cohort
study of
outcomes and
complications of
SIA for
occlusions of
infrainguinal
arteries in
patients with
CLI or IC
96 patients, 100
occlusions
88% 61% at 24 months,
but assisted
patency 68%
78% at 2 years 1b
Antusevas12 Prospective cohort
study of
outcomes and
complications of
SIA and PTA
73 SIA for SFA
occlusion in 71
patients
87.70% 65.8% at 24 months
but assisted
patency 68.5%
72.9% at 5 years 1b
Keeling11 Retrospective
series of patients
undergoing SIA
(mostly
infrainguinal) at
one centre
75 consecutive SIA
procedures (65
infrainguinal)
83% (62/75) 56.3% of patients
with IC (16 total)
symptom-free
(mean followup,
32 months; range,
1-64 months).
CLI had a
79.7% (total
59) limb
salvage rate at
a mean
follow-up of
30.7 months
(range, 0.5-
91 months).
2b
BASIL, Bypass versus Angioplasty in Severe Ischaemia of the Leg; BG, surgical femoro-popliteal bypass; CLI, critical limb ischemia; IC, intermittent
claudication; SIA, subintimal angioplasty; SFA, superficial femoral artery.
angio
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good evidence for the life-long use of antiplatelet agents in
any patient with sufficient peripheral vascular disease to
warrant angioplasty. But the place of drugs such as clopi-
dogrel and warfarin in the management algorithm remains
to be established.
Complications. Overall complication rates of SIA are
reported as between 6% and 17%. Definitions of complica-
tions differ widely, and there is very limited evidence about
factors affecting the complication rate (Table III). The
Table II. Comparison of outcomes between subintimal an
Study first
author Study design Intervention
No. of stu
patien
Watson14
Exersise
for IC
Systematic review of
randomized
controlled trials
to evaluate
exercise for IC in
patients with
PVD
Exercise
regimens vs
usual care
22 random
controlle
with 120
patients
Klinkert13
Outcomes
for
surgery
Systematic review of
randomized and
nonrandomized
surgical BG
patency in
patients with IC
or CLI
Infra-inguinal
above-knee
surgery
using leg
vein vs
PTFE
25 studies.
patients
venous b
2520 wit
PTFE by
BASIL7
Outcomes
for
surgery
Randomized
controlled trial of
angioplasty first
vs. surgery first in
CLI
SIA or BG 452 patien
27 hospi
presentin
CLI and
infraingu
disease
randomi
surgery fi
angiopla
Antusevas12
SIA vs
PTA
Prospective cohort
study of
outcomes and
complications of
SIA and PTA
SIA vs PTA 146 patien
chronic S
occlusion
and IC
Sultan9 SIA
vs Surgery
Prospective non-
randomized
controlled study
of SIA vs. BG in
patients with CLI
SA vs BG 96 patients
occlusion
ABPI, Ankle-brachial pressure index; BASIL, Bypass versus Angioplasty in Se
ischemia; IC, intermittent claudication; PTA, percutaneous transluminal
superficial femoral artery.complication rate of SIA is no higher than for PTA,15 andthe risk of major adverse events is lower in SIA than
surgery.10 The amputation rate after SIA was reported as
2.2% in patients with CLI and 0% (95% confidence interval
approximately 0%-0.5%) in patients with IC by Axisa et al.15
They also reported the major medical morbidity as 2.4%
and emergency surgical intervention required after 2.3% of
procedures. Two other important complications are vessel
perforation, which is easy to manage with embolization or
a covered stent, and distal embolus. A recently occluded
vessel must be approached with care, as there may be fresh
lasty and other strategies
Outcomes
Results/main
conclusions
Level of
Evidence for
therapy
evaluation
ls
Overall improvement
in walking ability
of 50%-200%.
ABPI not affected.
Exercise programmes
were of significant
benefit in
improving walking
time and distance.
1a
,
Primary patency of
infrainguinal
venous bypass
graft 81%, for a
PTFE graft 67% at
2 years
Autologous
saphenous vein
graft gives better
long-term patency
than PTFE graft.
1a/2a
h
r
st
No difference in
amputation-free
survival at 6
months (adjusted
hazard ratio 0.73,
95% CI 0.49-
1.07). Much loss
to follow-up in
longer-term data.
In CLI, “bypass
surgery first” and
“balloon
angioplasty first”
strategies are
associated with
broadly similar
outcomes in terms
of amputation-free
survival. In the
short term, surgery
is more expensive
than angioplasty.
1b
h At 12 months
patency is 71.2 vs
44.0 for SIA and
PTA, respectively.
At 24 months
patency is 68.5 vs
42.7 for SIA and
PTA, respectively.
Good outcomes with
SIA and good
patency (67%) at 1
year. Some bias
toward SIA as
more CLI in PTA
group.
2b
At 5 years, 72.8% for
SIA vs. 65.3% for
BG. 5 year
amputation-free
survival: 72.9% for
SIA vs. 71.2% for
BG.
SIA and BG similar
for long-term
patency and limb
salvage, but SIA
has a lower risk of
major adverse
events and lower
length of hospital
stay.
2b
schaemia of the Leg; BG, surgical femoro-popliteal bypass;CLI, critical limb
plasty; PTFE, polytetrafluoroethylene; SIA, subintimal angioplasty; SFA,giop
dies/
ts
ized
d tria
0
1284
with
ypass
h
pass.
ts from
tals
g wit
inal
zed to
rst o
sty fir
ts wit
FA
CLI
, 100
s
vere Ithrombus within it. In the study by Sultan et al,9 patients
JOURNAL OF VASCULAR SURGERY
November 20101414 Markose et alTable III. Complications and factors affecting outcomes for subintimal angioplasty
Study first
author Study design
No. of
studies/patients Complication rate
Factors affecting patency,
clinical outcome and
technical failure
Level of
evidence for
symptom
prevalence study
Klinkert13 Systematic review of
patency of infra-
inguinal above-
knee surgical bypass
grafts in patients
with IC or CLI
25 studies, 1284
patients with
venous bypass and
2520 with PTFE
bypass
Postoperative mortality
(18 studies): 2.2%
overall, 1.1% venous
bypass, 2.5% PTFE
bypass. Postop
wound infection (12
articles): venous
bypass 5.3%, PTFE
bypass 4.6%.
Use of autologous saphenous
vein graft increases long-
term patency.
1a
Twine17 Cochrane review of
randomized trials
of angioplasty alone
vs. angioplasty and
primary stenting in
TASC A and B
lesions in the SFA
in patients with IC
or CLI.
Eight trials with 968
patients
Patency for PTA plus
stent vs PTA alone
was 80% vs 70% at 6
months (P  .04),
and 70% vs 63% at
12 months (P 
.07), very small
numbers aat 2 years.
Although there is limited
benefit to stenting in the
SFA, this cannot be
recommended routinely.
1a-
Met6 Systematic review of
SIA outcomes in
peripheral arterial
occlusive disease
23 studies, 1549
patients
Reported rates varied
between 8 and 17%
Crural lesions have lower
rates of technical success
than SFA lesions
1a-/2a
Axisa15 Prospective case series
of patients
undergoing
angioplasty
evaluating
complication rates
for SIA vs PTA
1377 consecutive
interventional
procedures (48%
SIA, 52% PTA).
Approximately
2/3 for CLI and
1/3 for IC.
Major medical
morbidity 2.4%,
emergency surgical
intervention
required after 2.3%
of procedures (acute
limb ischaemia,
haemorrhagic
complications).
Amputation rate
following
angioplasty for CLI
was 2.2%, and for IC
0%. Complication
rate was similar for
SIA and PTA.
Not reported 1b
Sultan9 Prospective non-
randomized
controlled study of
SIA vs. BG in
patients with CLI
and infrainguinal
TASC II C/D
lesions
SIA 190, BG 119 Risk of major adverse
events and length of
hospital stay both
significantly lower in
the SIA group than
the surgical group.
Not reported 1b
Antusevas12 Prospective cohort
study of outcomes
and complications
of SIA and PTA in
patients with
chronic SFA
occlusion, CLI
and/or IC
146 patients Not reported SIA failures more common
when calcification noted
(P  .002)
1b
ABPI, Ankle-brachial pressure index; BG, surgical femoro-popliteal bypass; CLI, critical limb ischemia; IC, intermittent claudication; PTA, percutaneous
transluminal angioplasty; PTFE, polytetrafluoroethylene; SIA, subintimal angioplasty; SFA, superficial femoral artery; TASC, TransAtlantic InterSociety
Consensus.
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clot) were assigned for surgical management from the
outset.
DISCUSSION
The role of SIA is nowwell established for limb salvage in
critical ischemia,with highquality evidence for an angioplasty-
first strategy from the BASIL trial. The role of SIA in
intermittent claudication is evolving. In good hands, the
risks are no greater than for PTA, and a failed attempt at
SIA rarely precludes bypass surgery at a later date.21 In the
light of current concerns about hospital-acquired infection,
the use of bypass surgery as first line treatment may have to
be reconsidered. It is also important to recognize that the
risk of SIA is no higher than that of PTA, and their success
rates are comparable.
The long-term patency of SIA remains lower than that
of a bypass graft, but perhaps not as much lower as previ-
ously thought. Desgranges et al10 report a secondary pa-
tency of 68% at 2 years, which compares favourably with
PTFE graft patency of 67%, although still well below saphe-
nous vein graft patency of 81% at 2 years.13 This would
suggest subintimal angioplasty to be an appropriate inter-
vention for a claudicant with no available vein, particularly
given the low morbidity and mortality.
New strategies to further increase patency continue to
develop. Long-term patency of SIA and BG is related to the
number of patent runoff vessels and future evidence is likely
Table III. Continued
Study first
author Study design
No. of
studies/patients
Setacci8 Prospective case series
of SIA with adjuvant
use of the Outback
reentry device and
stenting in patients
presenting to a single
centre with CLI
145 SFA
angioplasties (24
using reentry device)
Ov
per
dis
(3)
pse
(2)
0.7
Bargellini18 Prospective case series
of SIA in diabetic
patients with CLI
at a single centre
Prospective. 60
consecutive
patients
Pe
m
a
Desgranges10 Prospective cohort
study of outcomes
and complications
of SIA for
occlusions of
infrainguinal
arteries in patients
with CLI or IC
96 patients, 100
occlusions (13%
of all infrainguinal
revascularisations
over the study
period). Presumed
reterospective
Ov
p
a
4
b
r
a
2
Keeling11 Retrospective case
series of patients
undergoing SIA
(mostly
infrainguinal) at
one centre
75 SIA procedures
(65 infrainguinal)
Noto emerge showing that recanalization of the runoff vesselsat the same time as femoro-popliteal SIA improves patency.
A new generation of stents and better anticoagulation may
also be of benefit. In the meantime, surveillance and early
reintervention are the best strategy. Finally, it is often
possible to perform a repeat procedure in the event of
reocclusion.
Quality of life and overall functional status are impor-
tant outcomes particularly in lifestyle limiting conditions
such as IC. These are not well captured by traditional
measurements such as survival and limb salvage, and have
not been assessed in relation to the individual procedures in
the published data. The importance of this is highlighted by
the study by Nehler et al22 who present data demonstrating
that more than half of patients who undergo major ampu-
tation never again become ambulatory, and nearly 20% of
these require care in a nursing facility.
There is a need for more high-quality evidence about
the optimal management of femoro-popliteal occlusive dis-
ease. A well-designed multi-center randomized controlled
trial of SIA vs BG vs medical management in patients with
intermittent claudication would be of great benefit. Such a
trial should include patient-reported outcomes such as
walking distance and quality of life. Subgroup analyses
could explore factors affecting patency and which groups of
patients derive most benefit. The role of antiplatelet agents
and anticoagulation after SIA should also be evaluated in a
randomized trial.
To conclude, SIA is an extremely valuable technique in
lication rate
Factors affecting patency,
clinical outcome and technical
failure
Level of
evidence for
symptom
prevalence study
.2% (9): arterial
n 2.1% (3),
bolisation 2.1%
ral artery
eurysm 1.4%
io-venous fistula
.
Factors independently affecting
patency: renal insufficiency,
current smoking and diabetes. 5
technical failures due to calcified
arteries or recoil. Use of
Outback re-entry device
increased technical success rate.
1b
edural
lity 5%, major
tation 5%.
Ulcer healing related to
serum creatinine, HbA1C
levels, diabetes duration,
infrapopliteal recanalisation
1b
17%: arterial
ation 6%,
l thrombosis
tensions
d the planned
y site 5%,
l dissection
Not reported 2b
orted Independent predictors of
avoiding CLI or IC after
successful revascularisation:
value of ABPI after
procedure and number of
patent runoff vessels.
2bComp
erall 6
foratio
tal em
, femo
udoan
, arter
% (1)
riproc
orta
mpu
erall
erfor
rteria
%, ex
eyon
eentr
rteria
%.
t repthe management of critical limb ischemia. Based on the
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November 20101416 Markose et alevidence to date, SIA is likely to have an increasing role in
themanagement of intermittent claudication over the com-
ing years.
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